Cancer Forums and News by PhD's

News | Forums

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News


Cancer Review


Recent Forum Topics

phase II
PF-3512676 (CPG 7909) Non-Small-Cell-Lung Immuno-modulatory Treatment Development History
By HCat at 2007-03-17 07:11

    Coley Phamaceutical Group has developed oligonucleotides which contain CpG motifs (the nucleotides cytosine and guanine in repetition) that help immune responses. The oligonucleotides illicit an immune response by affecting toll-like receptor (TLR) function, with the main one being TLR9. Here is a link to a basic picture of TLR function in the immune response from the company website. The CpG motifs in bacterial DNA have been shown years ago to illicit an immune response. Here is a link to an abstract of a paper on induction of an immune response by CpG motifs from bacterial DNA.

read more | 9120 reads

EntreMed Starts Phase II Clinical Trial of Panzem with Sutent for Kidney Cancer Patients
By HCat at 2007-03-13 03:58

    EntreMed, Inc has commenced a Phase 2 trial to evaluate the safety and efficacy of Panzem (2-methoxyestradiol; 2ME2) alone or in combination with Sutenttermterm (sunitinibterm) in patients with metastaticterm renal cell carcinomaterm. The University of Wisconsin, Paul P. Carbone Comprehensive Cancer Center will be the main center conducting the trial under the guidance of Dr. Glenn Liu. The trial will investigate Panzem’s potential to treat patients who are progressing on sunitinib.

     Panzem NCD uses Elan Drug Delivery's (Elan) NanoCrystal Colloidal Dispersion (NCD) technology, a technology that is being used in marketed pharmaceuticals. The NCD technology produces nanometer-sized particles, which are up to 500 times smaller than particles manufactured by conventional milling techniques. Panzem NCD works by blocking the VEGFterm receptor and by inhibiting HIF-1alpha. The theory behind Panzem’s anti-tumor effects is that renal cell cancers are frequently associated with VEGF and PDGF overexpression involving a HIF-1alpha mechanism. It is thought that patients who progress through the tyrosine kinase inhibitor response, such as those on the tyrosine kinase inhibitor sunitinib, have an increase in HIF-1alpha expression to compensate for the kinase inhibition in order to continue tumor growth. Dr. Liu has stated that this trial will test this hypothesis. Panzem NCD is also currently in Phase 2 clinical trials for brain, ovarian, carcinoid, and prostate cancers as well as in Phase 1 study in metastatic breast cancer.

read more | 6281 reads

Myriad Genetics Starts Azixa Phase II Clinical Trial for Brain Cancer Patients
By HCat at 2007-03-12 00:01

    Azixa (MPC-6827) has entered Phase II clinical trials in patients with primary brain cancer. Patients with glioblastoma multiforme (GBM) will be treated with Azixa, Azixa and oxaliplatintermterm, or oxalplatin alone and compared for survival rates. The 5 year survival rate of GBM stands at <3% and has remained unchanged for over 30 years. One problem with present cancer drugs is they cannot pass the blood-brain barrier (BBB) in efficiently high doses to act on the cancer. The BBB is the layer of tightly packed endothelial cells surrounding the brain preventing high-molecular weight molecules from entering the brain. Here is a quick reference to a good definition of the blood-brain barrier.

read more | 2367 reads

2007 Update of What is in the Oncology Pipeline at Glaxosmithkline
By HCat at 2007-03-07 07:05

    This is an update to the previous drug pipeline article covering 2006. Quite a few of the drugs from 2006 have been stopped with three new ones added.

559448, in license or other alliance relationship with a third party, is a thrombopoietin agonist indicated for use in thrombocytopaenia and in phase I

626616, in license or other alliance relationship with a third party, is a human kinase inhibitor indicated for use in chemoprotection and in phase I

read more | 5107 reads

Phase II Clinical Trial of Cytogens QUADRAMET with PSA-TRICOM Initiated for Hormone-Refractory Prostate Cancer Patients
By HCat at 2007-03-06 10:40

    At the beginning of March with the sponsorship of the National Cancer Institute (NCI), Cytogen Corporation it has initiated a randomized Phase II study to evaluate QUADRAMET (samarium Sm-153 lexidronam injection) in combination with PSA-TRICOM from the National Institute of Health (NIH). The patient base is for those who have failed docetaxel-based regimens.

    The study will determine if QUADRAMET alone or in combination with PSA-TRICOM can improve 4-month progression-free survival (PFS). There is currently no protocol for treatment of hormone-refractory patients who have advanced on docetaxel regimens.

    In April 2006, NCI researchers presented results of a preclinical study at the 97th Annual Meeting of the American Association for Cancer Research. The study, "Use of Samarium-153 (QUADRAMET) to modulate phenotype and enhance killing of tumor cells" demonstrated that exposure to QUADRAMET resulted in up-regulation of surface molecules on cancer cells, including Fas (CD95), carcinoembryonic antigen (CEA), mucin 1 (MUC-1), intercellular adhesion molecule-1 (ICAM-1 or CD54), and major histocompatibility complex class I (MHC-1). Each of the five molecules evaluated in the study has been implicated in enhancing anti-tumor T-cell responses through diverse mechanisms.

read more | 5244 reads

What Is in the Pipeline at GlaxoSmithKline?
By HCat at 2007-02-26 12:09

743921(In license or alliance with a third party), a kinesin spindle protein (KSP) inhibitor, is an indicated therapy for cancer in phase I trials.

Elacridar, an oral bioenhancer, is an indicated therapy for cancer is in phase I trials.

Relacatib (In license or alliance with a third party), a cathepsin K inhibitor, is an indicated therapy for bone metastases (also osteoporosis & osteoarthritis) in phase I trials

read more | 3031 reads

Syndicate content

sponsored links



Subscribe to our newsletter to receive info on our site or upcoming clinical trials

Confirm your email address

HTML format

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate

Syndicate content

All times are GMT -5. The time now is 12:28 PM.